Author pages are created from data sourced from our academic publisher partnerships and public sources.
Advances in malignant mesothelioma.
Malignant mesothelioma is an aggressive tumor of serosal surfaces, such as the pleura and the peritoneum. This tumor was once rare, but its incidence is increasing worldwide, probably as a result of… Expand
Integrative Molecular Characterization of Malignant Pleural Mesothelioma.
Malignant pleural mesothelioma (MPM) is a highly lethal cancer of the lining of the chest cavity. To expand our understanding of MPM, we conducted a comprehensive integrated genomic study, including… Expand
Cross-priming in health and disease
Cross-priming is an important mechanism to activate cytotoxic T lymphocytes (CTLs) for immune defence against viruses and tumours. Although it was discovered more than 25 years ago, we have only… Expand
Mesothelin-family proteins and diagnosis of mesothelioma
BACKGROUND Mesothelioma is a highly aggressive tumour for which there are no reliable serum tumour markers. Identification of such a marker would be useful in diagnosis of mesothelioma and for… Expand
Programmed Death Ligand 2 in Cancer-Induced Immune Suppression
- Esdy N. Rozali, Stanleyson V. Hato, B. Robinson, R. Lake, W. Lesterhuis
- Medicine, Biology
- Clinical & developmental immunology
- 29 April 2012
Inhibitory molecules of the B7/CD28 family play a key role in the induction of immune tolerance in the tumor microenvironment. The programmed death-1 receptor (PD-1), with its ligands PD-L1 and… Expand
Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors.
Cytotoxic chemotherapy is generally considered immunosuppressive, with neutropenia and lymphopenia being common adverse side effects. In this context, we have shown previously that the cytidine… Expand
Immunotherapy and chemotherapy — a practical partnership
This article discusses how recent data have altered the way we understand how dying tumour cells, particularly those killed by chemotherapy, engage with antitumour immune responses. These data have… Expand
Induction of Tumor Cell Apoptosis In Vivo Increases Tumor Antigen Cross-Presentation, Cross-Priming Rather than Cross-Tolerizing Host Tumor-Specific CD8 T Cells1
Cross-presentation of cell-bound Ags from established, solid tumors to CD8 cells is efficient and likely to have a role in determining host response to tumor. A number of investigators have predicted… Expand
Establishment of a murine model of malignant mesothelioma
- M. R. Davis, L. Manning, D. Whitaker, M. Garlepp, B. Robinson
- International journal of cancer
- 2 December 1992
Malignant mesothelioma (MM) is an aggressive tumour of the serosal cavities which is associated with previous asbestos exposure and is generally found to be resistant to conventional forms of… Expand
Tumor-Specific CD4+ T Cells Have a Major “Post-Licensing” Role in CTL Mediated Anti-Tumor Immunity1
A number of tumor studies have indicated a link between CD4 help and the magnitude and persistence of CTL activity; however, the mechanisms underlying this have been largely unclear. To evaluate and… Expand